2.99
price up icon10.33%   0.28
after-market アフターアワーズ: 2.99
loading
前日終値:
$2.71
開ける:
$2.89
24時間の取引高:
6.11M
Relative Volume:
0.70
時価総額:
$2.64B
収益:
$1.31M
当期純損益:
$-597.65M
株価収益率:
-3.0825
EPS:
-0.97
ネットキャッシュフロー:
$-425.62M
1週間 パフォーマンス:
+8.73%
1か月 パフォーマンス:
+8.33%
6か月 パフォーマンス:
-4.17%
1年 パフォーマンス:
-47.08%
1日の値動き範囲:
Value
$2.87
$3.01
1週間の範囲:
Value
$2.64
$3.01
52週間の値動き範囲:
Value
$1.83
$7.48

Immunitybio Inc Stock (IBRX) Company Profile

Name
名前
Immunitybio Inc
Name
セクター
Healthcare (1163)
Name
電話
(844) 696-5235
Name
住所
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
職員
671
Name
Twitter
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
IBRX's Discussions on Twitter

IBRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IBRX
Immunitybio Inc
2.99 2.39B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-20 アップグレード Piper Sandler Neutral → Overweight
2025-03-06 開始されました H.C. Wainwright Buy
2025-01-10 開始されました BTIG Research Buy
2023-05-12 ダウングレード Piper Sandler Overweight → Neutral
2022-08-03 開始されました Jefferies Buy

Immunitybio Inc (IBRX) 最新ニュース

pulisher
Jul 23, 2025

What analysts say about ImmunityBio Inc. stockHigh-yield market plays - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency - Yahoo Finance

Jul 23, 2025
pulisher
Jul 22, 2025

What drives ImmunityBio Inc. stock priceConsistently high yield - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is ImmunityBio Inc. a good long term investmentGame-changing returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga

Jul 22, 2025
pulisher
Jul 21, 2025

ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha

Jul 21, 2025
pulisher
Jul 20, 2025

ImmunityBio Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 15, 2025

ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView

Jul 15, 2025
pulisher
Jul 14, 2025

ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView

Jul 14, 2025
pulisher
Jul 12, 2025

ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha

Jul 12, 2025
pulisher
Jul 11, 2025

ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks

Jul 11, 2025
pulisher
Jul 10, 2025

Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN

Jul 10, 2025
pulisher
Jul 09, 2025

ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks

Jul 09, 2025
pulisher
Jul 09, 2025

ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

ImmunityBio: D. Boral Capital Maintains Buy, Raises PT to $30 from $30 - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN

Jul 08, 2025
pulisher
Jul 07, 2025

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard

Jul 07, 2025
pulisher
Jul 07, 2025

ImmunityBio's ANKTIVA® Secures UK Approval: A Catalyst for Global Oncology Leadership - AInvest

Jul 07, 2025
pulisher
Jul 07, 2025

Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire

Jul 07, 2025
pulisher
Jul 07, 2025

ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView

Jul 07, 2025
pulisher
Jul 06, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 06, 2025
pulisher
Jul 04, 2025

UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication - MarketScreener

Jul 04, 2025
pulisher
Jul 02, 2025

ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success - Insider Monkey

Jul 02, 2025
pulisher
Jun 24, 2025

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

Anktiva Approved For Additional Treatment - Los Angeles Business Journal

Jun 23, 2025
pulisher
Jun 20, 2025

ImmunityBio Approves 2025 Equity Incentive Plan - TipRanks

Jun 20, 2025
pulisher
Jun 17, 2025

ImmunityBio's $10.5M Investor Deal Gets Final OK - Law360

Jun 17, 2025
pulisher
Jun 17, 2025

ImmunityBio Gets Final OK for $10.5 Million Investor Settlement - Bloomberg Law News

Jun 17, 2025
pulisher
Jun 12, 2025

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment - pharmaphorum

Jun 12, 2025
pulisher
Jun 12, 2025

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - newswire.ca

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze (NASDAQ:IBRX) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion - MSN

Jun 12, 2025
pulisher
Jun 08, 2025

15 Stocks That Stole The Show Last Week - Insider Monkey

Jun 08, 2025
pulisher
Jun 06, 2025

Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView

Jun 06, 2025
pulisher
Jun 05, 2025

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

H.C. Wainwright maintains buy rating on ImmunityBio stock after FDA milestones - Investing.com Nigeria

Jun 04, 2025
pulisher
Jun 04, 2025

ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwr - GuruFocus

Jun 04, 2025

Immunitybio Inc (IBRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
大文字化:     |  ボリューム (24 時間):